nach oben

BioDrugs

Erschienen in:

01.03.2008 | Novel Therapeutic Stategies

Recombinant Human Growth Hormone

Rationale for Use in the Treatment of HIV-Associated Lipodystrophy

verfasst von: Stefano Benedini, Ileana Terruzzi, Adriano Lazzarin, Professor Livio Luzi

Erschienen in: BioDrugs | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The role of hormonal and metabolic alterations in HIV-associated lipodystrophy syndrome is not yet clear. In patients with HIV-1 undergoing antiretroviral treatment, lipodystrophy is associated with peripheral fat wasting and central adiposity, dyslipidemia, insulin resistance, and increased intramuscular fat accumulation.

In HIV lipodystrophy, changes in fat distribution are heterogeneous and can include reduced subcutaneous fat as well as increased visceral fat. In the literature, there is evidence showing that overnight growth hormone (GH) secretion and pulse amplitude decrease in patients with HIV lipodystrophy, with rates of response to standardized GH stimulation being abnormal in at least 20% of these patients.

Excess accumulation of visceral fat, central obesity, and increased intra-abdominal adiposity are also typical features of patients with GH deficiency. Recombinant human GH (rhGH) is a potential treatment to diminish excess visceral fat. Our group recently demonstrated that GH therapy in HIV-infected patients with syndromes of fat accumulation produced a significant decrease in body fat and a gain in lean tissue. In this article, we discuss the origin of lipodystrophy in HIV patients, and the use of rhGH treatment (benefits and adverse effects) in HIV-related lipodystrophy.

Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–8PubMedCrossRef

Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659–67PubMedCrossRef

van der Valk M, Allick G, Weverling GJ, et al. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J Clin Endocrinol Metab 2004; 89(7): 3554–60PubMedCrossRef

Ducobu J, Payen MC. Lipids and AIDS. Rev Med Brux 2000; 21: 11–7PubMed

Haugaard SB, Andersen O, Pedersen SB, et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006; 55(2): 175–82PubMedCrossRef

Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555–74PubMedCrossRef

Renard E, Fabre J, Paris F, et al. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 1999; 51: 223–30CrossRef

Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504–10PubMedCrossRef

Koutkia P, Canavan B, Breu J, et al. Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 2005; 90(1): 32–8PubMedCrossRef

10.

Murray RD, Adams JE, Shalet SM. Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 2004; 89: 1586–91PubMedCrossRef

11.

Boguszewski CL, Meister LH, Zaminelli DC, et al. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 2005; 152: 67–75PubMedCrossRef

12.

Luzi L, Perseghin G, Tambussi G, et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003 Feb; 284(2): E274–80PubMed

13.

Luzi L, Meneghini E, Oggionni S, et al. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. Eur J Endocrinol 2005; 153(6): 781–9PubMedCrossRef

14.

D’Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006; 84(1): 204–11PubMed

15.

Esposito GJ, Thomas SG, Kingdon L, et al. Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone. J Clin Endocrinol Metab 2006; 91(8): 2952–9PubMedCrossRef

16.

Andersen O, Haugaard SB, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest 2004; 34(8): 561–8PubMedCrossRef

17.

Kotier DP, Muurahainen N, Grunfeld C, et al. Serostim in Adipose Redistribution Syndrome Study Group. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 239–52CrossRef

18.

Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 2004; 38: 448–57PubMedCrossRef

19.

Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18: 465–73PubMedCrossRef

20.

Thomas SG, Esposito JG, Ezzat S. Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. J Clin Endocrinol Metab 2003; 88: 5737–8CrossRef

21.

Jorgensen JO, Krag M, Kanaley J, et al. Exercise, hormones, and body temperature regulation and action of GH during exercise. J Endocrinol Invest 2003; 26: 838–42PubMed

22.

Thomas SG, Esposito JG, Ezzat S. Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. J Clin Endocrinol Metab 2003; 88(12): 5734–8PubMedCrossRef

23.

de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306–12CrossRef

24.

Frank SJ. Growth hormone signalling and its regulation: preventing too much of a good thing. Growth Horm IGF Res 2001; 11: 201–12PubMedCrossRef

25.

Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537–43PubMedCrossRef

26.

Baumann G, Stolar MW, Amburn K, et al. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab 1986; 62: 134–41PubMedCrossRef

27.

Argetsinger LS, Carter-Su C. Mechanism of signaling by growth hormone receptor. Physiol Rev 1996; 76(4): 1089–107PubMed

28.

Xu BC, Wang X, Darus CJ, et al. Growth hormone promotes the association of transcription factor STAT5 with the growth hormone receptor. J Biol Chem 1996; 271(33): 19768–73PubMedCrossRef

29.

Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387(6636): 921–4PubMedCrossRef

30.

Greenhalgh CJ, Rico-Bautista E, Lorentzon M, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 2005; 115(2): 397–406PubMed

31.

Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12: 814–21PubMedCrossRef

32.

Carter-Su C, Rui L, Herrington J. Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol 2000; 14(7): 550–7PubMedCrossRef

33.

Richelsen B, Pedersen SB, Borglum JD, et al. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am J Physiol 1994; 266: E211–6PubMed

34.

Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev 2000; 1(2): 73–86PubMedCrossRef

35.

Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006; 17(2): 162–9PubMedCrossRef

36.

Reue K, Phan J. Metabolic consequences of lipodystrophy in mouse models. Curr Opin Clin Nutr Metab Care 2006; 9(4): 436–41PubMedCrossRef

37.

Kravcik S. HIV lipodystrophy: a review. HIV Clin Trial 2000; 1(3): 37–50CrossRef

38.

Hoffmann C, Rockstroh JK, Kamps BS. HIV medicine 2005. Cologne: Steinhäuser Verlag, 2005

39.

Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592–8PubMedCrossRef

40.

Viganò A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003; 32: 482–9PubMedCrossRef

41.

Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35–43PubMed

42.

Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25–32PubMedCrossRef

43.

Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309–61PubMedCrossRef

44.

Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51–7PubMedCrossRef

45.

Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257–62PubMedCrossRef

46.

Petit JM, Duong M, Duvillard L, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000; 32: 367–72PubMedCrossRef

47.

Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100(7): 700–5PubMedCrossRef

48.

Bonnet E, Ruidavets JB, Tuech J, et al. Apoprotein C-III and E-containing lipoprotein particles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001; 86(1): 296–302PubMedCrossRef

49.

Baril L, Beucler I, Valantin MA. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS 2001; 15(3): 415–7PubMedCrossRef

50.

Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 2004; 174(1): 1–10PubMedCrossRef

51.

Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130–9PubMedCrossRef

52.

Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251–4PubMedCrossRef

53.

Gnudi L, Shepherd PR, Kahn BB. Over-expression of GLUT4 selectively in adipose tissue in transgenic mice: implication for nutrient partitioning. Proc Nutr Soc 1996; 55: 191–9PubMedCrossRef

54.

Katz EB, Stenbit AE, Hatten K, et al. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT 4. Nature 1995; 377: 151–5PubMedCrossRef

55.

Tsao TS, Stenbit AE, Li J, et al. Muscle-specific transgenic complementation of GLUT4-deficient mice. J Clin Invest 1997; 100: 671–7PubMedCrossRef

56.

Mauras N, O’Brien KO, Welch S, et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000; 85: 1686–94PubMedCrossRef

57.

Kato Y, Murakami Y, Sohmiya M, et al. Regulation of human growth hormone secretion and its disorders. Inter Med 2002; 41(1): 7–13CrossRef

58.

Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. Obes Res 2003; 11: 170–5PubMedCrossRef

59.

Attallah H, Friedlander AL, Hoffman AR. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy. Growth Horm IGF Res 2006; 16Suppl. A: S62–7PubMedCrossRef

60.

Johannsson G, Mårin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82(3): 727–34PubMedCrossRef

61.

Franco C, Brandberg J, Lönn L, et al. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005; 90(3): 1466–74PubMedCrossRef

62.

Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 98(2): 379–81

63.

Carroll PV, Christ ER, Bengtsson B-Å, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382–95PubMedCrossRef

64.

Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 669–74PubMedCrossRef

65.

Shahi M, Beshyah SA, Hackett D, et al. Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality. Br Heart J 1992; 67: 92–6PubMedCrossRef

66.

Rosen T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8PubMedCrossRef

67.

Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol 1999; 50(1): 1–15CrossRef

68.

Menezes Oliveira JL, Marques-Santos C, Barreto-Filho JA, et al. Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab 2006; 91(6): 2093–9PubMedCrossRef

69.

Johansson JO, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin resistant. Metab Clin Exp 1995; 44: 1126–9PubMedCrossRef

70.

Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81: 555–64PubMedCrossRef

71.

De Boer H, Blok GJ, Voerman HJ, et al. Serum lipid levels in growth hormone-deficient men. Metab Clin Exp 1994; 43: 199–203PubMedCrossRef

72.

Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91(5): 1621–34PubMedCrossRef

73.

Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003; 148Suppl. 2: S9–14PubMedCrossRef

74.

Benedini S, Dalle Carbonare L, Albiger N, et al. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency. Horm Metab Res 2006; 38(1): 16–21PubMedCrossRef

75.

Colao A, Di Somma C, Savanellia MC, et al. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006; 16 Suppl.: 41–8CrossRef

76.

Svensson J, Bengtsson B-Å, Taskinen MR, et al. A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth Horm IGF Res 2000; 10(3): 118–26PubMedCrossRef

77.

Gola M, Bonadonna S, Doga M, et al. Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 2005; 90(3): 1864–70PubMedCrossRef

78.

Drake WM, Howell SJ, Monson JP, et al. Optimizing gh therapy in adults and children. Endocr Rev 2001 Aug; 22(4): 425–50PubMedCrossRef

79.

Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol 2004; 151Suppl. 1: S17–22PubMedCrossRef

80.

Renehan AG, Toogood AA, Ryder WD, et al. Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clin Endocrinol (Oxf) 2001; 55(4): 469–75CrossRef

81.

Allen DB, Rundle AC, Graves DA, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997; 131: S32–6PubMedCrossRef

82.

Wilton P. Adverse events during growth hormone treatment: 10 years experience in KIGS, a pharmacoepidemiological study. In: Ranke MB, editor. Growth hormone therapy in KIGS: 10 years experience. Leipzig: Johann Ambrosius Barth Verlag, 1999

83.

Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Horm Res 1997; 48Suppl. 4: 29–32PubMedCrossRef

84.

Gibney J, Johannsson G. Safety of growth hormone replacement therapy in adults. Expert Opin Drug Saf 2004 Jul; 3(4): 305–16PubMedCrossRef

85.

Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91(9): 3494–8PubMedCrossRef

86.

Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704–10PubMedCrossRef

87.

Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355: 610–3PubMedCrossRef

88.

Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006; 64(2): 115–21CrossRef

89.

Crawford BA, Cowell CT, Greenacre P, et al. Carbohydrate metabolism on high dose growth hormone therapy in children treated for leukaemia. Aust Paediatr J 1989; 25: 236–40PubMed

90.

Botero D, Danon M, Brown RS. Symptomatic non-insulin-dependent diabetes mellitus during therapy with recombinant human growth hormone. J Pediatr 1993; 123: 590–2PubMedCrossRef

91.

Svensson J, Fowelin J, Landin K, et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2121–7PubMedCrossRef

92.

Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1995; 80: 3209–22PubMedCrossRef

93.

Veldhuis JD, Iranmanesh A, Ho KK, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51–9PubMedCrossRef

94.

Ghigo E, Procopio M, Boffano GM, et al. Arginine potentiates but does not restore the blunted growth hormone response to growth-hormone releasing hormone in obesity. Metabolism 1992; 41: 560–3PubMedCrossRef

95.

Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 2813(8): 1000–2CrossRef

96.

Koutkia P, Canavan B, Breu J, et al. Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab 2005; 90(4): 2154–60PubMedCrossRef

97.

Kotier DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. Serostim in Adipose Redistribution Syndrome Study Group. J Acquir Immune Defic Syndr 2004; 1;35(3): 239–52CrossRef

98.

Andersen O, Haugaard SB, Hansen BR, et al. Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Scand J Infect Dis 2004; 36(11-12): 832–9PubMedCrossRef

99.

Haugaard SB, Andersen O, Hansen BR, et al. Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metabolism 2004; 53(12): 1565–73PubMedCrossRef

100.

Scacchi M, Pincelli AI, Cavagnini F, et al. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999; 23(3): 260–71PubMedCrossRef

101.

Sutinen J, Kannisto K, Korsheninnikova E, et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing’s syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004 Oct; 47(10): 1668–71PubMedCrossRef

102.

Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11 β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998; 83: 1325–35PubMedCrossRef

103.

Bujalska IJ, Kumar S, Hewison M, et al. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11 β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188–96PubMedCrossRef

104.

Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 1997; 349: 1210–3PubMedCrossRef

105.

Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11 β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002; 87: 5630–563PubMedCrossRef

106.

Filipsson H, Monson JP, Koltowska-Häggström M, et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006; 91(10): 3954–61PubMedCrossRef

107.

He Q, Engelson ES, Albu JB, et al. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol 2003; 94(5): 2051–7PubMed

108.

Tomlinson JW, Crabtree N, Clark PM, et al. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J Clin Endocrinol Metab 2003; 88(5): 2113–8PubMedCrossRef

109.

Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 2001; 56Suppl. 1: 1–6PubMedCrossRef

110.

Lauriola V. Effects of physical exercise in lipodystrophy HIV-related on metabolic parameters [in Italian; thesis]. Milan: Faculty of Exercise Sciences,University of Study of Milan, 2007 Mar

111.

Abdu TA, Neary R, Elhadd TA, et al. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 2001; 55(2): 209–16CrossRef

112.

Haugaard SB, Andersen O, Flyvbjergd A, et al. Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. J Infect 2006; 52(6): 389–98PubMedCrossRef

Titel: Recombinant Human Growth Hormone
Rationale for Use in the Treatment of HIV-Associated Lipodystrophy
verfasst von: Stefano Benedini
Ileana Terruzzi
Adriano Lazzarin
Professor Livio Luzi
Publikationsdatum: 01.03.2008
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 2/2008
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200822020-00003

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Recombinant Human Growth Hormone

Rationale for Use in the Treatment of HIV-Associated Lipodystrophy

Abstract

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Prostate Cancer Vaccines

Recombinant Factor VIIa (Eptacog Alfa)

Cell Adhesion Antagonists

Bevacizumab